

XP-000893154



ELSEVIER

European Journal of Pharmacology 342 (1998) 303–310

 cited in the European Search
 Report of EP 3937423.4
 Your Ref.: 60772-PC-EP

 RD 26/01/1998
 P 303-310 = 8

ejp

Glatiramer acetate blocks the activation of THP-1 cells by interferon- γ

Qingdi Li ^{a,b,c,d,2}, Ron Milo ^{a,d,3}, Hillel Panitch ^{a,d}, Peggy Swoveland ^{a,d},
 Christopher T. Bever Jr. ^{a,b,d,*}

^a Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA

^b Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA

^c Department of Microbiology, University of Maryland School of Dentistry, Baltimore, MD 21201, USA

^d Medical Research Service, Baltimore VA Medical Center, Baltimore, MD 21201, USA

Received 16 June 1997; revised 30 September 1997; accepted 7 November 1997

Abstract

Glatiramer acetate (previously known as copolymer 1) is a synthetic copolymer of four amino acids that has been approved for use in the treatment of multiple sclerosis. It has been shown to suppress myelin antigen specific T cell activation by competing with these antigens at the major histocompatibility complex class II binding site and by inducing antigen specific suppressor T cells. In this study we investigated the effects of glatiramer acetate on the human monocytic cell line, THP-1, activated by lipopolysaccharide and interferon- γ as a model for macrophages. At non-toxic concentrations of glatiramer acetate there were dose dependent reductions in the percentage of cells expressing human leukocyte DR and DQ antigen as well as in mean fluorescence intensity by flow cytometry. Production of tumor necrosis factor- α and the lysosomal cysteine proteinase cathepsin B were markedly inhibited, but production of interleukin-1 increased. These results suggest that glatiramer acetate might alter macrophage effector function and suggest that further studies in human monocytes and macrophages are warranted. Published by Elsevier Science B.V.

Keywords: Glatiramer acetate; HLA Class II; Cytokine; Cathepsin B; THP-1 cells; Multiple sclerosis

1. Introduction

Glatiramer acetate (previously called copolymer 1) is a synthetic basic copolymer of four amino acids (alanine, lysine, glutamic acid, and tyrosine) (Teitelbaum et al., 1971) that cross-reacts with myelin basic protein. It has been shown that glatiramer acetate can suppress clinical and pathological signs of experimental autoimmune encephalomyelitis induced by myelin basic protein (Arnon and Teitelbaum, 1988), proteolipid protein (Teitelbaum et al., 1996) or myelin oligodendrocyte glycoprotein (Rosbo et al., 1996) and reduce the exacerbation rate in

relapsing–remitting multiple sclerosis in double-blind, placebo-controlled clinical trials (Johnson et al., 1995). The mechanism of activity, however, is not fully understood. Previous studies indicated that glatiramer acetate specifically inhibits the T cell response to myelin basic protein in vitro by competing with it at the major histocompatibility complex class II binding site (Teitelbaum et al., 1992). It can also induce antigen-specific suppressor T cells in vivo that prevent development of experimental autoimmune encephalomyelitis and suppress myelin basic protein specific T cell activation (Aharoni et al., 1993). Human peripheral blood mononuclear cells often exhibit blastogenic responses to glatiramer acetate suggesting T cell recognition (Brosnan et al., 1985). However, little data is available on the effects of glatiramer acetate on antigen presentation by monocytes and macrophages, cells which are important in the pathogenesis of autoimmune diseases including multiple sclerosis (Prineas and Graham, 1981). Therefore, in this study we investigated the effects of glatiramer acetate on major histocompatibility complex class II molecule expression, synthesis of a lysosomal

* Corresponding author. Tel.: +1-410-6057061; fax: +1-410-6057937.

¹ These authors contributed equally to this work.

² Present address: Clinical Pharmacology Branch, Medical Ovarian Cancer Section, Developmental Therapeutics Department, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bldg. 10, Rm. 13N248, Bethesda, MD 20892, USA.

³ Present address: Department of Neurology, Assaf Harofeh Medical Center, Zerifin 70300, Israel.

cysteine proteinase cathepsin B which is implicated in demyelination (Yanagisawa et al., 1984) and production of the monocytic proinflammatory cytokines, tumor necrosis factor- α and interleukin-1 β , using the THP-1 cell line. This line is a human monocytic leukemia cell line with characteristics of macrophages including immunological functions, which serves as a useful model for studying the role of monocyte-macrophages in the human immune response (Auwerx, 1991). THP-1 cells can be induced to differentiate into macrophage-like cells by phorbol esters (Li and Bever, 1996) or by bacterial lipopolysaccharide (Li et al., 1997), and can be activated by interferon- γ (Li et al., 1994, 1997; Li and Bever, 1996). These macrophage-like cells express large amounts of major histocompatibility complex molecules (Li et al., 1994), produce large quantities of lysosomal proteinases (Li and Bever, 1996; Li et al., 1997) and secrete typical macrophage-associated cytokines including interleukin-1 β and tumor necrosis factor- α (Li et al., 1994), which may play important roles in the pathogenesis of inflammation and demyelination in multiple sclerosis (Selmaj and Raine, 1988; Durum and Oppenheim, 1989). In this report, we present results showing that glatiramer acetate could regulate these functions in our system in vitro.

2. Materials and methods

2.1. Drugs and reagents

Recombinant human interferon- γ was purchased from Genzyme (Cambridge, MA). Lipopolysaccharide (*E. coli*, 0111: B4), *N*-carbobenzoxy-(DL)-L-alanyl-L-arginyl-L-arginine-4-methoxy- β -naphthylamide, α -naphthylamide, brij 35, fast garnet, and trypan blue solution (0.4%) were purchased from Sigma Chemical (St. Louis, MO). Glatiramer acetate, composed of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine in a residual molar ratio of 4.2:1.4:3.4:1.0 (Batch #29035) was a gift from Teva Pharmaceutical (Petah-Tiqva). The THP-1 cell line was obtained from the American Type Culture Collection (Rockville, MD). RPMI 1640 medium, phosphate buffered saline (PBS), penicillin-G, streptomycin, L-glutamine, sodium pyruvate were purchased from Life Technologies (Gibco, Grand Island, NY). Fetal bovine serum was obtained from HyClone (Logan, UT).

2.2. Cells and cell culture

THP-1 cells were derived from a 1-year-old individual with acute monocytic leukemia and have monocyte-macrophage characteristics (Tsuchiya et al., 1980). These cells were grown in 75 cm² plastic tissue culture flasks (Corning, Corning, NY) in 20 ml of RPMI 1640 medium supplemented with the antibiotics penicillin-G (50 U/ml) and streptomycin (50 μ g/ml), 10% (v/v) heat-inactivated

fetal bovine serum, L-glutamine (2 mM), *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid buffer (HEPES) (5 mM) (GIBCO BRL, Gaithersburg, MD), pH 7.3 (cRPM sodium pyruvate (1 mM), in logarithmic growth at 37°C in a humidified atmosphere consisting of 5% CO₂: 95% air. Cells were routinely tested for mycoplasma infection using a commercial assay system (Mycotect; GIBCO BRL) and new cultures were established monthly from frozen stocks. All media and reagents contained <0.1 ng/ml endotoxin as determined by *Limulus polyphemus* amoebocyte lysate assay (Whittaker Bioproducts, Walkersville, MD). Cell viability was determined by trypan blue exclusion. Before starting the experiments, the cells were grown for 1 day after subculturing. Subculturing was done by harvesting the cells, resuspending in cell culture medium and culturing them at 5×10^5 cells/ml. Differentiation of THP-1 cells was assessed by observing adherence and morphology. Cells were incubated with lipopolysaccharide and where indicated, glatiramer acetate for 24 h, then the medium was removed and replaced with fresh medium containing interferon- γ . The cells were harvested for use in the cathepsin B assay 48 h later. Interferon- γ was used at a saturating dose of 500 U/ml in these experiments and lipopolysaccharide was used at a dose of 25 μ g/ml unless otherwise indicated.

2.3. Flow cytometric analysis

THP-1 cells were pretreated with various concentrations of lipopolysaccharide, interferon- γ , or glatiramer acetate as described. After an incubation period, cells were harvested, washed twice with phosphate buffered saline (PBS), counted, and resuspended at 5×10^5 viable cells per 50 μ l of PBS supplemented with 2% fetal bovine serum and 0.1% sodium azide in 5 ml polypropylene tubes. Samples were then stained with 5 μ l of phycoerythrin-conjugated mouse anti-human leukocyte antigen-DR or fluorescein isothiocyanate (FITC)-conjugated mouse anti-human leukocyte antigen-DQ or the appropriate isotype control (Olympus, Lake Success, NY). After incubation on ice for 15 min, cells were washed twice, fixed with 0.5 ml of 0.5% paraformaldehyde, and analyzed for percentage of human leukocyte antigen-DR or human leukocyte antigen-DQ positive cells and mean fluorescence intensity in an Epics Elite flow cytometer (Coulter, Hialeah, FL). Gains were adjusted to include 100% of the viable cells, and 5000 cells per sample were counted.

2.4. Cytokine assays

The culture supernatants were collected after 48 h of incubation under the conditions described. The quantities of these cytokines were measured using human tumor necrosis factor- α or interleukin-1 β enzyme-linked immunosorbent assay (ELISA) kits from R + D System (Minneapolis, MN); the detection limits for these kits were

15 pg/ml for tumor necrosis factor- α and 10 pg/ml for interleukin-1 β , respectively. The antibodies in these kits did not have any detectable cross-reactivity with other antigens. In accordance with the manufacturer's instructions the samples were incubated in duplicate wells and read on an automated ELISA reader (Anthos-Labtec Instruments, Salzburg).

2.5. Cathepsin B assay

A standard assay based on the release of naphthalamine from an artificial substrate was used (Barrett and Kirschke, 1981). Stimulated THP-1 cells were harvested by gentle scraping with a disposable rubber cell scraper (Costar, Cambridge, MA). Cells were washed 3 times with PBS (pH 7.0), counted, and 5×10^5 cells were aliquoted for assay. Cells were resuspended in PBS (pH 6.0) and lysed by freeze-thawing and sonication 3 times. The resulting lysate was then assayed in triplicate by a previously described assay based on the release of naphthylamine from an artificial substrate (Bever et al., 1989). In brief, aliquots of supernatants prepared by centrifugation were added to activation buffer to give 250 μ l containing 100 mM phosphate and 1 mM ethylenediaminetetraacetic acid (EDTA), pH 6.0. After 5 min, *N*-carbobenzoxy-(DL)-L-

alanyl-L-arginyl-L-arginine-4-methoxy- β -naphthylamide (40 mg/ml), a substrate not degraded by cathepsin H and L (Barrett and Kirschke, 1981) in dimethyl sulfoxide (DMSO) was added. The mixture was incubated at 37°C for 50 min, then the reaction was stopped with the addition of the color reagent, mersalyl-EDTA in Brij 35 with Fast Garnet. After mixing well, the mixture was left at room temperature for approximately 10 min for color development. The samples were read on a spectrophotometer (Stasar II; Gilford, Oberlin, OH) at 520 nm. The assays were standardized with α -naphthylamide and results expressed as nanomoles of naphthylamine released per million cells or mg protein in the lysate.

3. Results

3.1. The effect of glatiramer acetate on human leukocyte antigen-DR and -DQ expression on THP-1 cells

As shown by flow cytometric analysis, 66% of unstimulated THP-1 cells were positive for human leukocyte antigen-DR, and 10% for human leukocyte antigen-DQ (Fig. 1A and B; Table 1). Stimulation of the cells with 25 μ g/ml of lipopolysaccharide for 24 h followed by 500




Fig. 1. The effect of glatiramer acetate on cell surface human leukocyte antigen-DR and human leukocyte antigen-DQ expression on THP-1 cells. THP-1 cells cultured for 72 h in the absence of lipopolysaccharide, interferon- γ and glatiramer acetate (A and B). THP-1 cells cultured for 24 h in the presence of 25 μ g/ml lipopolysaccharide followed by 48 h with 500 U/ml interferon- γ (C and D). THP-1 cells cultured with 25 μ g/ml lipopolysaccharide and 20 μ g/ml glatiramer acetate for 24 h followed by 500 U/ml interferon- γ for 48 h (E and F). The cells were then analyzed by flow cytometry for the molecules indicated, as described in Section 2.

Table 1

The effect of glatiramer acetate on human leukocyte antigen-DR and human leukocyte antigen-DQ expression on THP-1 cells^a

Treatment ^b	HLA-DR		HLA-DQ	
	positive ^c (%)	fluorescence ^d (mean)	positive ^c (%)	fluorescence ^d (mean)
None	66	2.5	10	0.37
LPS + IFN- γ	96	53.0	44	2.46
(LPS + 5 μ g/ml Cop 1) + IFN- γ	89	40.4	30	2.31
(LPS + 10 μ g/ml Cop 1) + IFN- γ	93	38.8	39	2.23
(LPS + 20 μ g/ml Cop 1) + IFN- γ	76	11.6	19	0.97

^a Representative fluorescence profiles are given in Fig. 1.^b Cells incubated for 24 h in media containing 25 μ g/ml of lipopolysaccharide (LPS). Medium was then removed and replaced with fresh medium containing 500 U/ml of interferon- γ (IFN- γ). Cells were harvested after 48 h of incubation. Glatiramer acetate (Cop 1) was added to the first incubation at the concentrations given.^c Percent positive cells relative to the irrelevant antibody control.^d Mean fluorescence intensity of the positive cells.

U/ml of interferon- γ for 48 h upregulated the expression of human leukocyte antigen-DR and -DQ (Fig. 1C and D). As shown in Table 1, the percentage of positive cells increased to 96.4% and 44%, respectively, after treatment with lipopolysaccharide and interferon- γ . Incubation of the cells with 20 μ g/ml glatiramer acetate for 24 h decreased the number of stained cells to 76% and 19%, respectively (Fig. 1E and F; Table 1). Untreated cells showed low mean fluorescence intensity values for human leukocyte antigen-DR and -DQ (Table 1). Lipopolysaccharide and interferon- γ additively increased the density of these cell surface molecules (data not shown). Treatment of the THP-1 human monocytes in culture with lipopolysaccharide and interferon- γ caused striking increases in both human leukocyte antigen-DR and human leukocyte antigen-DQ mean fluorescence intensity (Table 1). Addition of glati-

ramer acetate to the stimulated cells inhibited class II human leukocyte antigen expressions by up to 80% in concentration-dependent manner (Fig. 1E and F; Table 1).

3.2. The effect of glatiramer acetate on cytokine production and cathepsin B activity in THP-1 cells

Production of two major macrophage cytokines, interleukin-1 β and tumor necrosis factor- α , was measured. Unstimulated cells produced nearly undetectable levels of both substances, while large amounts were induced by stimulation with lipopolysaccharide and interferon- γ (Fig. 2). Glatiramer acetate at a non-toxic concentration of 20 μ g/ml inhibited tumor necrosis factor- α production by 80% (Fig. 2), but stimulated the production of interleukin-1 β by approximately 50% (Fig. 2). The inhibition of tumor necrosis factor- α production by up to 60% was confirmed also in a bioassay using L929 cells (data not shown). The effect of interferon- γ on the intracellular




Fig. 2. The effect of glatiramer acetate (cop 1) on the production of tumor necrosis factor- α and interleukin-1 β in lipopolysaccharide-primed THP-1 cell cultures by interferon- γ . Cells were incubated with lipopolysaccharide (25 μ g/ml) in the presence or absence of glatiramer acetate (cop 1) for 24 h, the medium was changed to fresh medium containing interferon- γ (500 U/ml) for an additional 24 h and supernatants were then collected and assayed for tumor necrosis factor- α and interleukin-1 β as described in Section 2. IL-1- β , interleukin-1 β ; Cop 1, glatiramer acetate; LPS, lipopolysaccharide; TNF- α , tumor necrosis factor- α ; IFN- γ , interferon- γ .




Fig. 3. The effect of glatiramer acetate (cop 1) on cathepsin B activity in THP-1 cells. Cells were seeded at a density of 5×10^5 cells/ml in 75 cm flasks and cultured for 24 h in the presence of 25 μ g/ml of lipopolysaccharide. The medium was then changed to fresh medium containing 500 U/ml of interferon- γ and cells were incubated for an additional 48 h. Cells were then harvested and assayed for cathepsin B activity as described in Section 2. Glatiramer acetate (cop 1) at the indicated concentrations was added during the initial incubation time. The results are the mean of triplicate determinations. IFN- γ , interferon- γ ; CB, cathepsin B; LPS, lipopolysaccharide; Cop 1, glatiramer acetate.

activity of an inducible lysosomal cysteine proteinase, cathepsin B, was also studied using the human monocytic cell line, THP-1. We have shown previously that there were basal low levels of cathepsin B in unstimulated cells. Stimulation of lipopolysaccharide-primed THP-1 cells with interferon- γ increased cathepsin B activity. The effect of interferon- γ was dose- and time-dependent (Li et al., 1997). Incubation with glatiramer acetate for 24 h effectively blocked the interferon- γ -induced increase in monocyte cathepsin B activity (Fig. 3). The toxicity of glatiramer acetate concentrations from 2.5 to 150 $\mu\text{g/ml}$ was examined by cell recovery, trypan blue dye exclusion, and ^{51}Cr release cytotoxicity assay (data not shown) and concentrations of 50 $\mu\text{g/ml}$ and above were found to be toxic. The concentrations of glatiramer acetate used in these experiments were not toxic.

4. Discussion

In this report, we used THP-1 cells as a model of human monocytes and macrophages and studied the effect of glatiramer acetate on the modulation of expression of major histocompatibility complex class II molecules and synthesis of cytokines and cathepsin B. We demonstrated here for the first time that glatiramer acetate downregulates lipopolysaccharide and interferon- γ -induced expression of human leukocyte antigen-DR and -DQ in THP-1 human monocytic/macrophage-like cells. Glatiramer acetate also effectively blocked the interferon- γ -induced increase in tumor necrosis factor- α production and cathepsin B activity, but upregulated the production of interleukin- 1β by approximately 50% in lipopolysaccharide-primed THP-1 cells. These results differ from those in a previously published study in which we found no effect (Milo and Panitch, 1995), but those studies differed significantly from the present studies in that the cell line was a B lymphocyte transformed by Epstein-Barr virus infection and only the effect of glatiramer acetate on unstimulated class II antigen expression was examined. These differences suggest that future studies should examine human monocytes and macrophages.

Activated monocytes and macrophages are important in the pathogenesis of multiple sclerosis. Macrophages are found in lesions, actively phagocytizing myelin lamella and ingesting immunoglobulins bound to myelin (Prineas and Graham, 1981). Peripheral blood monocytes are activated in multiple sclerosis and exhibit augmented release of arachidonic acid metabolites (Merrill et al., 1989), toxic oxygen intermediates (Fisher et al., 1988), hydrolytic enzymes (Cieri and Bever, 1990; Bever et al., 1994), and cytokines (Merrill et al., 1989) compared to cells of normal individuals. Monocytes within multiple sclerosis plaques in the brain are also activated and express major histocompatibility complex class II molecules (Traugott et al., 1983). These studies together suggest that activated

macrophages are important in multiple sclerosis pathogenesis.

The mechanism of action of glatiramer acetate, which was developed to prevent the development of experimental allergic encephalomyelitis, is not known. Glatiramer acetate suppresses acute experimental autoimmune encephalomyelitis in various animal species (Teitelbaum et al., 1971; Sela et al., 1990) and chronic-relapsing experimental autoimmune encephalomyelitis in guinea pigs (Keith et al., 1979), and reduced relapse rate and improved disability in relapsing-remitting multiple sclerosis on a phase III multicenter, double-blind, placebo-controlled clinical trial (Johnson et al., 1995). Two possible mechanisms were proposed for the activity of glatiramer acetate in experimental autoimmune encephalomyelitis and multiple sclerosis: (i) induction of antigen-specific suppressor cells (Aharoni et al., 1993); and (ii) competition with myelin antigens for activation of antigen specific T cell lines (Teitelbaum et al., 1992, 1996; Milo and Panitch, 1995; Rosbo et al., 1996). Evidence showed that glatiramer acetate can inhibit the response to myelin basic protein of various myelin basic protein-specific T cell lines only in the presence of antigen-presenting cells, indicating that the site of action of glatiramer acetate is probably on the major histocompatibility complex class II molecules (Teitelbaum et al., 1992). Racke et al. (1992) have reported that glatiramer acetate can suppress responses of murine T cells to antigens other than myelin basic protein and postulated that blockade of antigen presentation was related to the restriction element involved rather than to the specific antigen. Together, these studies suggest that one of the possible mechanisms of inhibition of glatiramer acetate is to interfere with antigen presentation which in turn interferes with T cell activation.

It is generally accepted that processing of a protein antigen by an antigen-presenting cell and its presentation as a complex with self-major histocompatibility complex molecules are prerequisites for antigen recognition by T lymphocytes via their T cell receptors, leading to T cell activation. CD4^+ T cells recognize the antigenic peptide bound to major histocompatibility complex class II-antigens on antigen-presenting cells. Regulation of class II antigen expression on the surface of antigen-presenting cells is a critical step in the control of immune responses (Unanue et al., 1984). Human leukocyte antigen-DR and -DQ are the principal class II molecules operative in antigen-recognition by autoreactive CD4^+ T cells in multiple sclerosis patients (Martin et al., 1990; Ota et al., 1990; Pette et al., 1990). Blockade of the interferon- γ -induced increases in human leukocyte antigen-DR and -DQ expression on antigen-presenting cell by glatiramer acetate could be one of the mechanisms which controls the deleterious effects of interferon- γ in multiple sclerosis. We have shown that glatiramer acetate blocks the increases in human leukocyte antigen-DR and -DQ expression induced by lipopolysaccharide and interferon- γ treatment of THP-1

cells. Two further steps are needed to determine the significance of this effect. It must be shown that glatiramer acetate has a similar effect on stimulated class II antigen expression on human monocytes and macrophages and that antigen presenting function is inhibited.

The major cell wall component of Gram-negative bacteria, lipopolysaccharide, is a potent activator of macrophage responses involved in the host defense against infection (Adams and Hamilton, 1992; Rietschel and Brade, 1992). Interferon- γ , a T cell-derived cytokine, also regulates monocyte activation and effector function including modulation of major histocompatibility complex antigen expressions (Li et al., 1994; Li and Bever, 1996). Activated monocytes produce cytokines such as interleukin-1 β and tumor necrosis factor- α (Adams and Hamilton, 1992; Li et al., 1994), which are likely to contribute to myelin damage and local inflammation (Selmaj and Raine, 1988; Durum and Oppenheim, 1989). Tumor necrosis factor- α regulates immune responses (Old, 1987), damages myelin-forming oligodendroglia (Selmaj and Raine, 1988; Soliven et al., 1991), and stimulates astrocyte proliferation in vitro (Selmaj et al., 1990). Interleukin-1 and tumor necrosis factor- α activate T cells and mediate the perivascular demyelination and gliosis characteristic of multiple sclerosis plaques (Hofman et al., 1989; Selmaj et al., 1990). Glatiramer acetate has differential effects on cytokine expression in our system, with inhibition of tumor necrosis factor- α and enhancement of interleukin-1 β . The exact mechanism for this effects is not clear. However, tumor necrosis factor- α has shown to amplify major histocompatibility complex class II gene induction (Chang and Lee, 1986; Arenzana-Seisdedos et al., 1988), while interleukin-1 β downregulates it (Johnson et al., 1989; Smith et al., 1993), the effect of glatiramer acetate on these cytokines correlates with its effect on human leukocyte antigen-DR and -DQ. However, other factors may be involved because no change was seen in class II antigen expression at 5 μ g/ml glatiramer acetate, a concentration which increased IL-1 β production.

Cathepsin B (EC 3.4.22.1), a lysosomal cysteine proteinase, is implicated in myelin basic protein degradation (Yanagisawa et al., 1984). It is increased in the peripheral blood monocytes and macrophages of multiple sclerosis patients (Bever, 1991; Bever and Garver, 1992a,b; Bever et al., 1994), and in multiple sclerosis lesions (Bever and Garver, 1992a,b, 1995), and is induced in macrophages after interferon- γ treatment (Cieri and Bever, 1990). It is possible that during multiple sclerosis exacerbations, macrophages in multiple sclerosis lesions are activated by interferon- γ and produce proteinases which participate in demyelination and result in the fragments of myelin basic protein which are found in the cerebral spinal fluid of multiple sclerosis patients. In addition, the role of these enzymes might not be limited to the degradation of extracellular matrix (Barrett and Kirschke, 1981; Maciewicz and Wotton, 1991; Cardozo et al., 1992), but also may be

related to the presentation of antigen to the major histocompatibility complex class II (Matsunaga et al., 1993). In this regard, it has been shown that cathepsin B has a role in cleaving invariant chains from class II major histocompatibility complex molecules (Reyes et al., 1991; Reyes and Cresswell, 1991; Daibata et al., 1994; Mizuochi et al., 1994) and a role in the processing and presentation of class II major histocompatibility complex-restricted antigens (Reyes et al., 1991; Matsunaga et al., 1993). Therefore, it is possible that cathepsin B participates in the processing and presentation of myelin basic protein peptides to the immune system and enhances immune response. Glatiramer acetate inhibits the increases in cathepsin B activity induced by lipopolysaccharide and interferon- γ and could indirectly interfere with antigen presentation and T cell activation. This mechanism could contribute to the effect of glatiramer acetate on multiple sclerosis disease activity.

In summary, we have shown a downregulating effect of glatiramer acetate on lipopolysaccharide and interferon- γ -induced THP-1 cell human leukocyte antigen-DR and -DQ expression, cathepsin B activity, and tumor necrosis factor- α production. Our findings suggest that glatiramer acetate could downregulate class II human leukocyte antigen expression and tumor necrosis factor- α production and decrease cathepsin B activity associated with monocytes and macrophages in vivo. These findings suggest that the benefit of glatiramer acetate seen in clinical trials in multiple sclerosis patients could in part be due to an effect on monocytes and macrophages. Further studies using human monocytes and macrophages, examining additional cytokines implicated in multiple sclerosis will be needed.

Acknowledgements

This work was supported by grants from the National Multiple Sclerosis Society and the Department of Veterans Affairs (to CTB). Dr. Qingdi Li was supported by postdoctoral fellowship from the University of Maryland School of Medicine and Baltimore Veterans Affairs Medical Center.

References

- Adams, D.O., Hamilton, T.A., 1992. Molecular basis of macrophage activation: Diversity and its origins. In: Lewis, L.E., McGee, J.C. (Eds.), *The Macrophage: The Natural Immune System*. IRL Press, Oxford, pp. 75–105.
- Aharoni, R., Teitelbaum, D., Arnon, R., 1993. T suppressor hybridoma and interleukin-2-dependent lines induced by copolymer 1 on spinal cord homogenate down-regulate experimental allergic cephalomyelitis. *Eur. J. Immunol.* 23, 17–25.
- Arenzana-Seisdedos, F., Mogensen, S., Vuillier, F., 1988. Autosecretion of tumor necrosis factor under the influence of interferon- γ amplifies HLA-DR gene induction in human monocytes. *Proc. Natl. Acad. Sci. USA* 85, 6087–6091.
- Arnon, R., Teitelbaum, D., 1988. Suppression of demyelinating disease by synthetic copolymers. In: Sertupli-Crescenzi, G. (Ed.), *A Multi*

- disciplinary Approach to Myelin Disease. Plenum Press, New York, pp. 234–250.
- Auwerx, J., 1991. The human leukemia cell line, THP-1: A multifaceted model for the study of monocyte-macrophage differentiation. *Experimentia* 47, 22–30.
- Barrett, A.J., Kirschke, H., 1981. Cathepsin B, cathepsin H, and cathepsin L. *Methods Enzymol.* 80, 535–561.
- Bever, C.T., 1991. Cathepsin B in peripheral blood mononuclear cells of multiple sclerosis patients. *Trans. Am. Soc. Neurochem.* 22, 208.
- Bever, C.T., Garver, D.W., 1992a. Increased cathepsin B activity in multiple sclerosis lesions. *Trans. Am. Soc. Neurochem.* 23, 214.
- Bever, C.T., Garver, D.W., 1992b. Cathepsin B activity in multiple sclerosis lesions: Cellular origins. *Neurochem. Int.* 21 (Suppl.), C18.
- Bever, C.T., Garver, D.W., 1995. Increased cathepsin B activity in multiple sclerosis brain. *J. Neurol. Sci.* 131, 71–73.
- Bever, C.T., Snyder, D.S., Endres, R.O., Morgan, K.D., Postlethwaite, A., Whitaker, J.N., 1989. Activation of astrocytic lysosomal proteinases by factors released by mononuclear leukocytes. *Neurochem. Res.* 14, 37–41.
- Bever, C.T., Panitch, H.S., Johnson, K.P., 1994. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. *Neurology* 44, 745–748.
- Brosnan, C.F., Litwak, M., Neighbour, P.A., Lyman, W.D., Carter, T.H., Bornstein, M.B., Bloom, B.R., 1985. Immunogenic potentials of copolymer I in normal human lymphocytes. *Neurology* 35, 1754–1759.
- Cardozo, C., Kurtz, C., Lesser, M., 1992. Degradation of rat lung collagens by cathepsin B. *J. Lab. Clin. Med.* 119, 169–175.
- Chang, R.J., Lee, S.H., 1986. Effects of interferon- γ and tumor necrosis factor- α on the expression of an Ia antigen on a murine macrophage cell line. *J. Immunol.* 137, 2853–2856.
- Cieri, M., Bever, C.T., 1990. Gamma interferon induced increases in cathepsin B activity are blocked by alpha and beta interferons (Type I interferon). *FASEB J.* 4, A339.
- Daibata, M., Xu, M., Humphreys, R.E., Reyes, V.E., 1994. More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. *Mol. Immunol.* 31, 255–260.
- Durum, S.C., Oppenheim, J.J., 1989. Macrophage-derived mediators: Interleukin 1, tumor necrosis factor, interleukin 6, and related cytokines. In: Paul, W. (Ed.), *Fundamental Immunology*. Raven Press, New York, pp. 639–661.
- Fisher, M., Levine, P.H., Weiner, B.H., 1988. Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis. *Inflammation* 12, 123–131.
- Hofman, F.M., Hinton, D.R., Johnson, K., 1989. Tumor necrosis factor identified in multiple sclerosis brain. *J. Exp. Med.* 170, 607–612.
- Johnson, W.J., Kelley, A., Connor, J.R., 1989. Inhibition of IFN- γ -induced Ia antigen expression on synovial fibroblasts by β -1. *J. Immunol.* 143, 1614–1618.
- Johnson, K.P., Brooks, B.R., Cohen, J.A., 1995. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. *Neurology* 45, 1268–1276.
- Keith, A.B., Arnon, R., Teitelbaum, D., 1979. The effect of Cop1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. *J. Neurol. Sci.* 42, 267–274.
- Li, Q., Bever, C.T., 1996. Gamma interferon induced increases in intracellular cathepsin B activity in PMA primed THP-1 cells are blocked by inhibitors of protein kinase C. *Immunopharmacol. Immunotoxicol.* 18, 375–396.
- Li, Q., Milo, R., Bever, C.T., Swoveland, P., Panitch, H., 1994. Protein kinase C regulates HLA class II molecule expressions and TNF- α production in THP-1 cells. *FASEB J.* 8, A506.
- Li, Q., Falkler, W.A., Bever, C.T., 1997. Endotoxin induces increased intracellular cathepsin B activity in THP-1 cells. *Immunopharmacol. Immunotoxicol.* 19, 215–237.
- Maciewicz, R.A., Wotton, S.F., 1991. Degradation of cartilage matrix components by the cysteine proteinases, Cathepsin B and L. *Biomed. Biochim. Acta* 50, 561–564.
- Martin, R., Jaraquemada, D., Flerlage, M., 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. *J. Immunol.* 145, 540–548.
- Matsunaga, Y., Saibara, T., Kido, H., Katunuma, N., 1993. Participation of cathepsin B in processing of antigen presentation to MHC class II. *FEBS Lett.* 324, 325–330.
- Merrill, J.E., Strom, S.R., Ellison, G.W., 1989. In vitro study of mediators of inflammation in multiple sclerosis. *J. Clin. Immunol.* 9, 84–96.
- Milo, R., Panitch, H., 1995. Additive effects of copolymer-1 and interferon β -1b on the immune response to myelin basic protein. *J. Neuroimmunol.* 61, 185–193.
- Mizuochi, T., Yee, S.T., Kasai, M., Kakiuchi, T., Muno, D., Kominami, E., 1994. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. *Immunol. Lett.* 43, 189–193.
- Old, L.J., 1987. Polypeptide mediator network. *Nature* 326, 330–331.
- Ota, K., Matsui, M., Milford, E.L., 1990. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. *Nature* 346, 183–187.
- Pette, M., Fujita, K., Wilkinson, D., 1990. Myelin autoreactivity in multiple sclerosis: Recognition of myelin-basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. *Proc. Natl. Acad. Sci. USA* 87, 7968–7972.
- Prineas, J.W., Graham, J.S., 1981. Multiple Sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. *Ann. Neurol.* 10, 149–158.
- Racke, M.K., Martin, R., McFarland, H., 1992. Copolymer-1 induced inhibition of antigen-specific T cell activation: Interference with antigen presentation. *J. Neuroimmunol.* 37, 75–84.
- Reyes, V.E., Lu, S., Humphreys, R.E., 1991. Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains. *J. Immunol.* 146, 3877–3880.
- Rietschel, E.T., Brade, H., 1992. Bacterial endotoxins. *Sci. Am.* 267, 54.
- Roche, P.A., Cresswell, P., 1991. Proteolysis of the class II associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. *Proc. Natl. Acad. Sci. USA* 88, 3150–3154.
- Rosbo de Kerlero, N., Mendel, I., Milo, R., Flechter, S., Ben-Nun, A., 1996. The autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis and MOG-induced experimental autoimmune encephalomyelitis: Effect of copolymer-1. *Eur. J. Neurol.* 3 (Suppl. 4), 57–58.
- Sela, M., Arnon, R., Teitelbaum, D., 1990. Suppressive activity of Cop-1 in EAE and its relevance to multiple sclerosis. *Bull. Inst. Pasteur (Paris)* 88, 303–314.
- Selmaj, K.W., Raine, C.S., 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. *Ann. Neurol.* 23, 339–346.
- Selmaj, K.W., Farooq, M., Norton, W.T., 1990. Proliferation of astrocytes in vitro in response to cytokines: A primary role for tumor necrosis factor. *J. Immunol.* 144, 129–135.
- Smith, M.E., McFarlin, D.E., Dhib-Jalbut, S., 1993. Differential effect of interleukin-1 β on Ia expression in astrocytes and microglia. *J. Neuroimmunol.* 46, 97–104.
- Soliven, B., Szuchet, S., Nelson, D.J., 1991. Tumor necrosis factor inhibits K⁺ current expression in cultured oligodendrocytes. *J. Membr. Biol.* 124, 127–137.
- Teitelbaum, D., Meshorer, A., Hirshfeld, T., 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. *Eur. J. Immunol.* 1, 242–248.
- Teitelbaum, D., Milo, R., Arnon, R., 1992. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. *Proc. Natl. Acad. Sci. USA* 89, 137–141.
- Teitelbaum, D., Fridkis-Hareli, M., Arnon, R., Sela, M., 1996. Copolymer 1 inhibits chronic relapsing experimental allergic en-

- cephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. *J. Neuroimmunol.* 64, 209–217.
- Traugott, U., Reinherz, E.L., Raine, C.S., 1983. Multiple sclerosis distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. *J. Neuroimmunol.* 4, 201–221.
- Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., Tada, K., 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). *Int. J. Cancer* 26, 171–176.
- Unanue, E.R., Beller, D.J., Lu, C.Y., 1984. Antigen presentation: Comments on its regulation and mechanism. *J. Immunol.* 132, 1–4.
- Yanagisawa, K., Sato, S., Miyatake, T., Kominami, E., Katsunuma, N., 1984. Degradation of myelin protein by cathepsin B and inhibition by E-64 analogue. *Neurochem. Res.* 9, 691–694.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/04121

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4428965	31-01-84	CA-A- 1164473 JP-C- 1584103 JP-B- 2007932 JP-A- 55162717	27-03-84 22-10-90 21-02-90 18-12-80
WO-A-9211859	23-07-92	NONE	
WO-A-9207952	14-05-92	AU-B- 1272292 CA-A- 2095323 EP-A- 0555418 JP-T- 6506056	26-05-92 01-05-92 18-08-93 07-07-94

Form PCT/ISA/210 (patent family annex) (July 1992)